Bayer Starts Phase II Study NIRVANA to Evaluate Elinzanetant in Women with Sleep Disturbances Associated with Menopause

Berlin, January 8, 2024– Bayer, a global leader in women’s healthcare, announced today the expansion of the clinical development program for the investigational compound elinzanetant. The first study participants were recently enrolled...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials